<DOC>
	<DOCNO>NCT00513279</DOCNO>
	<brief_summary>GSK618334 develop innovative treatment substance dependence potentially compulsive behavioral disorder . This study evaluate safety , tolerability pharmacokinetics single dos GSK618334 healthy volunteer .</brief_summary>
	<brief_title>To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<criteria>Healthy adult male subject , age 18 50 year age inclusive . Body weight â‰¥50 kg BMI within range 18.529.9 kg/m2 inclusive . Healthy judge responsible physician . No clinically significant abnormality identify medical , psychiatric laboratory evaluation , include 12lead ECG 24 hour Holter ECG . A subject clinical abnormality laboratory parameter ( ) outside reference range age group may include Investigator considers find introduce additional risk factor interfere study procedure . Signed date write informed consent prior participation study . The subject able understand comply protocol requirement , instruction protocolstated restriction . The subject positive prestudy urine drug screen include alcohol screen visit and/or prior receive first dose study medication . Drugs screen amphetamine , barbiturate , cocaine , opiates , cannabinoids , methadone , benzodiazepine , phencyclidine ( PCP ) cotinine . If test positive investigator may retest subject subject may include retest negative . A positive prestudy Hepatitis B surface antigen , Hepatitis C antibody , HIV 1/2 result screen visit . Abuse alcohol define average weekly intake great 28 unit average daily intake great 4 unit . The subject clinically significant elevation liver function test ( LFT ) elevate reference range prestudy screen remain elevated repeat LFT , and/or prior receive first dose study medication . Consumption grapefruit juice grapefruit within 7 day prior receive first dose study medication . Any subject prepare eat standard meal provide Clinical Pharmacology Research Unit ( CPRU ) study . Participation clinical trial new chemical entity within 4 month first dose study medication market compound within 3 month receive first dose study medication . Use prescription nonprescription drug , include , counter remedy , vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior receive first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . Loss 600mL blood 120 day study start . History presence allergy study drug drug class , history allergy , opinion physician responsible , contraindicate participation study . History regular use tobacco nicotinecontaining product within 6 month start study ( i.e. , Screening Visit 1 ) . An unwillingness male subject use condom practise abstinence prevent exposure female partner semen start study ( i.e. , Screening Visit 1 ) 90 day study treatment end . History psychiatric disorder either Axis I II DSMIV . History presence respiratory illness , gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . The subject screening ECG value outside range define protocol . The subject screening heart rate &lt; 50 &gt; 100 bpm systolic blood pressure &gt; 140 &lt; 100 mmHg diastolic blood pressure &gt; 90 &lt; 60 mmHg semisupine position . The subject reduction systolic blood pressure 20 mmHg , reduction diastolic blood pressure 10 mmHg standing compare supine measurement screening . History long QT syndrome ( personal family ) cardiac conduction disorder , clinically significant cardiac disease . The subject unable abstain strenuous physical activity 24 h prior screen visit 24 h prior admission treatment period . Inability subject successfully trained test cognition prior receive first dose study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Safety ,</keyword>
	<keyword>tolerability ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>pharmacodynamics ,</keyword>
	<keyword>repeat dose ,</keyword>
	<keyword>placebo ,</keyword>
	<keyword>GSK618334</keyword>
</DOC>